12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Referencer<br />
Definition<br />
Bacigalupo A, Hows J, Gluckman E. Bone Marrow Transplantation (BMT) versus immune suppression <strong>for</strong> the<br />
treatment of severe anaemia (SAA): A report of the EBMT SAA working party. Br J Haematol 70: 177-182,<br />
1988.<br />
Immunsuppression<br />
Gluckman E, Esperou-Bourdeau H, Baruchel A. Multicenter randomized study comparing cyclosporin-A alone<br />
and antithymocyte globulin with prednsone <strong>for</strong> treatment of severe aplastic anemia. Blood 79: 2540-2546, 1992.<br />
Frickhofen N, Kaltwasser JP, Schrezenmeier H. Treatment of aplastic anemia with antilymphocyte globulin and<br />
methylprednisolone with or without cyclosporine. New Engl J Med 324: 1297-1304, 1998.<br />
Frickhofen N, HeimpelH, Kaltwasser J P, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A:<br />
11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101: 1236-1242, 2003.<br />
Tidlige <strong>KMT</strong>-resultater<br />
Bacigalupo A, Brand R, Oneto R. Treatment of acquired severe aplastic anemia: Bone marrow transplantation<br />
compared with immunosuppressive therapy - the european group <strong>for</strong> blood and marrow transplantation<br />
experience. Seminars in Hematol 37: 69-80, 2000.<br />
Bacigalupo A, Oneto R, Bruno B. Current results of bone marrow transplantation in patients with acquired severe<br />
aplastic anemia. Acta Haematol 103: 19-25, 2000.<br />
Passweg JR, Pérez WS, Eapen M, Camitta BM, Glückman E, Hinterberger W, Hows JM, Marsh JCW, Pasquini<br />
R, Schrezenmeier H, Socie G, Zhang M-J, Bredeson C. Bone marrow transplants from mismatch related and<br />
unrelated donors <strong>for</strong> severe aplastic anemia. Bone Marrow Transplantation 37: 641-9, 2006.<br />
Nyere <strong>KMT</strong>-resultater<br />
Storb R, Blume KG, O’Donnell MR, Chauncey T, Forman SJ, Deeg HJ, Hu WW, Appelbaum FR, Doney K,<br />
Flowers ME, Sanders J, Leisenring W. Cyclophosphamide and antithymocyte globulin in condition patients with<br />
aplastic anemia <strong>for</strong> allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow<br />
Transplant 7: 39-44, 2001.<br />
Kahl C, Leisenring W, Deeg HJ, Chauncey TR, FlowersM E, Martin PJ, Sanders JE, Storb R. Cyclophosphamide<br />
and antithymocyte globulin as a conditioning regimen <strong>for</strong> allogeneic marrow transplantation in patients with<br />
aplastic anaemia: a long-term follow-up. Br J Haematol 130: 747-51, 2005.<br />
Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajewski JL, Te M, Ramsey N, Harris RE, Castro-Malaspina<br />
H, Collins R, Champlin Schoch G, King R, Howe C. Marrow transplantation from unrelated donors <strong>for</strong> patients<br />
with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 5: 243-<br />
252, 1999,<br />
Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, Oneto R, Passweg JR. Improved outcome of<br />
patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation <strong>for</strong> severe<br />
acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning<br />
regimen. Haematologica 94: 1312-15, 2009.<br />
97
Change language